Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.

Molecular cancer research : MCR - 1 Feb 2016

Gannon Hugh S, Kaplan Nathan, Tsherniak Aviad, Vazquez Francisca, Weir Barbara A, Hahn William C, Meyerson Matthew

Abstract excerpt

UNLABELLED: The identification of somatic genetic alterations that confer sensitivity to pharmacologic inhibitors has led to new cancer therapies. To identify mutations that confer an exceptional dependency, shRNA-based loss-of-function data were analyzed from a dataset of numerous cell lines to reveal genes that are essential in a small subset of cancer cell lines. Once these cell lines were determined, detailed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Delivery Systems

Share to MAP Kinase Kinase 1

Share to Pyridones

Share to Pyrimidinones

Share to RNA Interference

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26582713
DOI: 10.1158/1541-7786.MCR-15-0321
PMCID: PMC4755909

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.PMID 26582713Read ↗

Genome-wide profiling identifies the genetic dependencies of cell death following EGFR inhibitionSemantic proximity Read ↗

Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening.Semantic proximity Read ↗

Integrated Molecular Characterisation of the MAPK Pathways in Human CancersSemantic proximity Read ↗

Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies.Semantic proximity Read ↗

In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancerSemantic proximity Read ↗

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.Semantic proximity Read ↗

Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential.Semantic proximity Read ↗

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.Semantic proximity Read ↗

A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization.Semantic proximity Read ↗

Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinomaSemantic proximity Read ↗

An Isogenic Cell Line Panel for Sequence-based Screening of Targeted Anti-cancer DrugsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.